Adaptive Biotechnologies

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Adaptive Biotechnologies reports robust Q4 performance and eyes growth opportunities

Adaptive Biotechnologies delivered strong financial performance in Q4 2022 and full-year 2022, driven by growth in MRD and immune medicine segments, showcasing operational efficiency and revenue expansion.
While facing challenges such as paused T-Detect commercialization and revenue phasing complexities, the company is well-positioned to capitalize on opportunities like market acceptance of MRD and drug discovery partnerships.
With a positive revenue outlook for 2023, supported by strategic initiatives and a strong cash position, Adaptive Biotechnologies is poised for continued growth and market leadership in the biotechnology sector.

Adaptive Biotechnologies reports robust Q1 revenue and growth prospects

Adaptive Biotechnologies showcased strong revenue growth and operational improvements in Q1 2023.
The company is strategically positioned to capitalize on opportunities in MRD business and immune medicine segment.
Challenges include potential impacts from regulatory changes and the need for milestone achievements.
Overall, Adaptive Biotechnologies remains focused on growth, innovation, and expanding its market presence.

Adaptive Biotechnologies reports revenue growth and strategic partnerships in Q2

Adaptive Biotechnologies demonstrated solid revenue growth and margin improvement in Q2 2023, with a strategic outlook for future profitability.
Strong partnerships with Genentech and advocacy for MRD as a clinical endpoint position the company for continued success in the market.
Ongoing challenges in pricing and integration efforts are being addressed, while opportunities in drug discovery and AI-driven target discovery offer growth potential.

Adaptive Biotechnologies reports Q3 revenue growth amidst industry challenges

Adaptive Biotechnologies saw mixed performance with MRD growth and Immune Medicine decline.
Company's focus on MRD profitability and novel target identification shows strategic strength.
Facing challenges from industry softening and cost pressures but eyeing revenue growth opportunities.
Maintaining long-term target of $1,600 in 2027 while making progress towards profitability.

Adaptive Biotechnologies reports mixed Q4 results, focuses on MRD growth

Adaptive Biotechnologies navigated a transformative year in 2023, with a strong focus on MRD and Immune Medicine businesses. The company faces challenges in Immune Medicine revenue decline and achieving profitability. Strategic initiatives and partnerships position the company for growth and innovation in the biotechnology sector.

Adaptive Biotechnologies posts solid Q1 results, eyes breakeven targets

Adaptive Biotechnologies reported strong MRD revenue growth and aims to reduce operating expenses significantly in 2024. Despite a net loss, the company updated full-year guidance with a focus on achieving breakeven targets by 2025 and 2026. Opportunities lie in MRD segment expansion and immune medicine development.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.

Adaptive's immunoSEQ T-MAP COVID provides potential explanation for preservation of Johnson & Johnson vaccine (Ad26.COV2.S) response to variants even when neutralizing antibodies are diminished Adaptive's immunoSEQ T-MAP COVID provides potential explanation for preservation of Johnson & Johnson vaccine (Ad26.COV2.S) response to variants even when neutralizing antibodies are diminished

New Study Published in Nature Provides Further Evidence that COVID-19 Vaccine Induced T-Cell Response Targets Known SARS-CoV-2 Variants of Concern

Studies demonstrate value of MRD in novel treatment settings including CAR T cell therapy and in a growing range of patient types, including Non-Hodgkin's Lymphoma Studies demonstrate value of MRD in novel treatment settings including CAR T cell therapy and in a growing range of patient types, including Non-Hodgkin's Lymphoma

Adaptive Biotechnologies Included in More than 20 Abstracts at ASCO and EHA 2021 Highlighting Expanding Use Cases for MRD Testing with the clonoSEQ® Assay in Blood Cancer Patients

SEATTLE, May 20, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating virtually in the following investor conferences.

Adaptive Biotechnologies to Participate in Upcoming June 2021 Investor Conferences

Adaptive Biotechnologies Corporation (ADPT) CEO Chad Robins on Q1 2021 Results - Earnings Call Transcript

SEATTLE, May 05, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2021.

Adaptive Biotechnologies Reports First Quarter 2021 Financial Results

Adaptive Biotechnologies (NASDAQ:ADPT) announces its next round of earnings this Wednesday, May 05. Here is Benzinga's everything-that-matters guide for this Wednesday's Q1 earnings announcement.

Earnings Outlook for Adaptive Biotechnologies

Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Adaptive Biotechnologies (ADPT) Q1 Earnings Expected to Decline

SEATTLE, April 27, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming BofA Securities 2021 Virtual Healthcare Conference.

Adaptive Biotechnologies to Present at the BofA Securities 2021 Virtual Healthcare Conference

Barnwell Industries

GenMark Diagnostics

Roche Holding AG

Meridian Bioscience

Meridian Bioscience Inc. (NASDAQ:VIVO) edged out GenMark Diagnostics Inc. (NASDAQ:GNMK) as the top gainer in the March GenomeWeb Index with a 25% boost in its share price compared to GenMark's 22.5% increase. At the other end of the spectrum were Adaptive Biotechnologies Corp. (NASDAQ:ADPT), whose shares plummeted 28%, Burning Rock Biotech (BRN) with a 25% decline and Quanterix Corp. (QNTX), which fell 22.8%.

GenomeWeb Index Drops 3% for 2nd Consecutive Month

SEATTLE, April 12, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT)  a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2021 after market close on Wednesday, May 5, 2021. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Adaptive Biotechnologies to Report First Quarter Financial Results on May 5, 2021

SEATTLE, March 17, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the appointments of Leslie Trigg and Katey Owen, Ph.D. to its Board of Directors effective immediately. The collective commercial and scientific expertise of these industry leaders will strengthen Adaptive's ability to execute against its open-ended growth story. The company also announced that Eric Dobmeier and David Goel will retire from the Board after long-standing tenures.

Adaptive Biotechnologies Strengthens Expertise and Diversity of Board of Directors with Appointments of Leslie Trigg and Katey Owen

Amgen

BioNTech SE

Illumina

Moderna

Microsoft

The confluence of healthcare and technology will send many biotech stocks soaring over the next decade.

Why You Should Own Biotech Stocks Now

The shares of Adaptive Biotechnologies Corp (NASDAQ:ADPT) are sinking even lower today, following a price-target cut to $60 from $68 from Guggenheim.

Analyst Bear Note Sends ADPT Stock Even Lower

The stock price of Adaptive Biotechnologies Corporation (Nasdaq: ADPT) has increased by over 10% pre-market. This is why it happened.

ADPT Stock Price Increases Over 10% Pre-Market: Why It Happened

The FDA issued the Emergency Use Authorization (EUA) to Adaptive Biotechnologies Corp's (NASDAQ: ADPT) T-Detect COVID-19 Test on Friday. It will be used to determine whether an individual had been infected with SARS-CoV-2 in the past.

Adaptive Biotechnologies Secures FDA EUA For COVID-19 T-Cell Response Test

First and only clinical T cell-based test for patients to detect the unique T-cell signature specific to SARS-CoV-2, the virus that causes COVID-19

Adaptive Biotechnologies Announces FDA Emergency Use Authorization for T-Detect™ COVID to Confirm Recent or Prior COVID-19 Infection

Oracle

Virgin Galactic

Tesla

Citrix Systems

Danaher

DocuSign

With the trading day about halfway over, the broad markets have not made up their minds on a direction for the day.

Microsoft, Oracle, Tesla, Virgin Galactic and More Wednesday Afternoon Analyst Calls

SEATTLE, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Cowen 41st Annual Healthcare Conference.

Adaptive Biotechnologies to Present at the Cowen 41st Annual Healthcare Conference

Adaptive Biotechnologies' (ADPT) CEO Chad Robins on Q4 2020 Results - Earnings Call Transcript

Seattle-based Adaptive Biotechnologies, which sequences the human immune system to diagnose and treat disease, posted revenue of $30.

Adaptive Biotech revenue up 25%; company launches T-cell test for past COVID-19 infections

Shares of Adaptive Biotechnologies (NASDAQ:ADPT) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 94.12% year over year to ($0.33), which missed the estimate of ($0.29).

Adaptive Biotechnologies: Q4 Earnings Insights

SEATTLE, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2020.

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2020 Financial Results

Adaptive Biotechnologies Corp (NASDAQ: ADPT) launched a clinical T-cell-based test kit to confirm recent or prior COVID-19 infection.  T-Detect is currently under review by the FDA for Emergency Use Authorization.

Adaptive Bio Launches T-Cell Based COVID-19 Tests

SEATTLE, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced an expansion of its collaboration with Labcorp (NYSE:LH), a leading global life sciences company, to enable broader access to Adaptive's growing portfolio of immune-driven clinical diagnostic and research products. The expanded collaboration includes a commercial agreement for Adaptive's clonoSEQ® and immunoSEQ® assays and a lab services agreement for Adaptive's recently launched T-Detect COVID™ test, the first clinical T-cell based test for patients to confirm recent or prior COVID-19 infection.

Adaptive Biotechnologies Expands Collaboration with Labcorp to Increase Access to Growing Research and Clinical Diagnostic Portfolio

T-Detect is currently under review by the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA)

News for Adaptive Biotechnologies Stock (ADPT)